title: Characterization of bacterial isolates collected from a sheep model of osseointegration.
abstract: Percutaneous osseointegrated implant technology provides a potential alternative to current socket prosthetics for individuals with limb loss. However, similar to other percutaneous devices, there remain concerns of periprosthetic infection. To understand this process of infection, bacterial isolates were collected and characterized from a sheep model of osseointegration. CSA-13, a novel cationic steroid antimicrobial, was used at the skin/implant interface in an attempt to reduce the rate of infection. Results indicated that in this application, normal flora and environmental organisms continued to colonize the skin/implant interface as well as cause infection in the presence of CSA-13. Two factors are believed to have contributed to this outcome: the delivery of CSA-13 and the lack of a skin seal at the skin/implant interface, which would create a biological barrier to infection.
authors.affiliation: Associated Regional and University Pathologists (ARUP) Laboratories, ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA. dustin.williams@utah.edu
authors.forename: Dustin L
authors.initials: DL
authors.lastname: Williams
authors.forename: Roy D
authors.initials: RD
authors.lastname: Bloebaum
authors.forename: James P
authors.initials: JP
authors.lastname: Beck
authors.forename: Cathy A
authors.initials: CA
authors.lastname: Petti
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology; D001419:Bacteria / Q000145:classification* / Q000302:isolation & purification*; D004195:Disease Models, Animal; D005260:Female; D008826:Microbial Sensitivity Tests; D016348:Osseointegration; D016459:Prosthesis-Related Infections / Q000382:microbiology* / Q000517:prevention & control*; D012756:Sheep; D013256:Steroids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D013256:Steroids; C521528:ceragenin CSA-13
references.citation: J Anat. 2006 Jul;209(1):59-67
references.pmid: 16822270
references.citation: Antimicrob Agents Chemother. 2008 Aug;52(8):2890-7
references.pmid: 18490507
references.citation: J Bone Joint Surg Br. 2008 Jan;90(1):114-21
references.pmid: 18160512
references.citation: Lancet. 1999 Jan 2;353(9146):51-6
references.pmid: 10023965
references.citation: Scand J Plast Reconstr Surg. 1982;16(1):17-21
references.pmid: 7112035
references.citation: Biomaterials. 2006 Aug;27(23):4183-91
references.pmid: 16618500
references.citation: Clin Infect Dis. 2008 Jul 1;47(1):73-82
references.pmid: 18484878
references.citation: J Biomed Mater Res A. 2008 May;85(2):366-70
references.pmid: 17688277
references.citation: J Periodontol. 2008 May;79(5):836-44
references.pmid: 18454662
references.citation: Arch Surg. 1998 Nov;133(11):1241-6
references.pmid: 9820357
references.citation: Biomaterials. 1997 Jul;18(14):969-78
references.pmid: 9212192
references.citation: Clin Infect Dis. 1998 Jun;26(6):1341-5
references.pmid: 9636860
references.citation: J Rehabil Res Dev. 2001 Mar-Apr;38(2):175-81
references.pmid: 11392650
references.citation: Transpl Infect Dis. 2007 Jun;9(2):114-20
references.pmid: 17461996